{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:47:19Z","timestamp":1761490039372},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","labmed.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.cll.2016.05.010","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T17:57:31Z","timestamp":1466877451000},"page":"473-491","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia"],"prefix":"10.1016","volume":"36","author":[{"given":"Gualberto","family":"Rua\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Seip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Windemuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H.B.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2016.05.010_bib1","series-title":"Prescription and price trends October 2005 to December 2006 and\u00a0potential cost savings to Medicare from increased use of lower cost statins. Consumer Reports. 2-19-2007. Yonkers, NY, Consumers Union., in Consumer Reports","author":"Findlay","year":"2007"},{"key":"10.1016\/j.cll.2016.05.010_bib2","unstructured":"Visiongain L. Statins: the world market, 2009-2024. London: 2009."},{"issue":"1","key":"10.1016\/j.cll.2016.05.010_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.amjcard.2006.01.066","article-title":"What the statin trials have taught us","volume":"98","author":"Waters","year":"2006","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.cll.2016.05.010_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.cll.2016.05.010_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0002-9149(98)00421-4","article-title":"Efficacy and safety of simvastatin 80\u00a0mg\/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group","volume":"82","author":"Stein","year":"1998","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.cll.2016.05.010_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40\u00a0mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"issue":"15","key":"10.1016\/j.cll.2016.05.010_bib7","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.97.15.1446","article-title":"Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial","volume":"97","author":"Sacks","year":"1998","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.cll.2016.05.010_bib9","first-page":"11","article-title":"Common and rare gene variants affecting plasma LDL cholesterol","volume":"29","author":"Burnett","year":"2008","journal-title":"Clin Biochem Rev"},{"issue":"2","key":"10.1016\/j.cll.2016.05.010_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ng.75","article-title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans","volume":"40","author":"Kathiresan","year":"2008","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.cll.2016.05.010_bib11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa0706728","article-title":"Polymorphisms associated with cholesterol and risk of cardiovascular events","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.cll.2016.05.010_bib12","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.cll.2016.05.010_bib13","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.107.708388","article-title":"Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment","volume":"117","author":"Krauss","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cll.2016.05.010_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2007.12.004","article-title":"Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER","volume":"200","author":"Polisecki","year":"2008","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.cll.2016.05.010_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/CIRCGENETICS.108.818062","article-title":"Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort","volume":"2","author":"Thompson","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"issue":"4","key":"10.1016\/j.cll.2016.05.010_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FPC.0b013e3282f60aad","article-title":"Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study","volume":"18","author":"Donnelly","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.cll.2016.05.010_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2143\/AC.61.3.2014836","article-title":"Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)","volume":"61","author":"Maitland-van der Zee","year":"2006","journal-title":"Acta Cardiol"},{"issue":"1","key":"10.1016\/j.cll.2016.05.010_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1463-1326.2006.00577.x","article-title":"Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus","volume":"9","author":"Tavintharan","year":"2007","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.cll.2016.05.010_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0021-9150(01)00410-5","article-title":"Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner","volume":"158","author":"Pedro-Botet","year":"2001","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.cll.2016.05.010_bib20","first-page":"401","article-title":"Lack of association between the APOE genotype and the response to statin treatment in patients with acute ischemic episodes","volume":"130","author":"Sousa","year":"2008","journal-title":"Med Clin (Barc)"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1365-2796.2002.00991.x","article-title":"Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting","volume":"251","author":"Pena","year":"2002","journal-title":"J\u00a0Intern Med"},{"issue":"16","key":"10.1016\/j.cll.2016.05.010_bib22","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/eurheartj\/ehm196","article-title":"Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study","volume":"28","author":"Chiodini","year":"2007","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/sj.tpj.6500328","article-title":"An association study of 43 SNPs in 16 candidate genes with atorvastatin response","volume":"5","author":"Thompson","year":"2005","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"10.1016\/j.cll.2016.05.010_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2125.2007.02892.x","article-title":"SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients","volume":"64","author":"Zhang","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib25","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/01.CIR.103.6.792","article-title":"Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment","volume":"103","author":"Zambon","year":"2001","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.cll.2016.05.010_bib26","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s10038-006-0025-1","article-title":"Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy","volume":"51","author":"Takane","year":"2006","journal-title":"J\u00a0Hum Genet"},{"issue":"3","key":"10.1016\/j.cll.2016.05.010_bib27","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1152\/physrev.00023.2007","article-title":"Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics","volume":"88","author":"Hirokawa","year":"2008","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/j.cll.2016.05.010_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacc.2007.10.017","article-title":"Polymorphism in KIF6 gene and\u00a0benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study","volume":"51","author":"Iakoubova","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.cll.2016.05.010_bib29","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jama.298.11.1300","article-title":"Association of apolipoprotein E genotypes with lipid levels and coronary risk","volume":"298","author":"Bennet","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cll.2016.05.010_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCGENETICS.108.773168","article-title":"Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication","volume":"1","author":"Chasman","year":"2008","journal-title":"Circ Cardiovasc Genet"},{"issue":"2","key":"10.1016\/j.cll.2016.05.010_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.76","article-title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease","volume":"40","author":"Willer","year":"2008","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib32","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1073\/pnas.0508483103","article-title":"Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels","volume":"103","author":"Cohen","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"12","key":"10.1016\/j.cll.2016.05.010_bib33","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cll.2016.05.010_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/14622416.6.8.865","article-title":"Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis","volume":"6","author":"Rua\u00f1o","year":"2005","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.cll.2016.05.010_bib35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","article-title":"Physiogenomic association of statin-related myalgia to serotonin receptors","volume":"36","author":"Rua\u00f1o","year":"2007","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.cll.2016.05.010_bib36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/pgs.10.58","article-title":"Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?","volume":"11","author":"Rua\u00f1o","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.cll.2016.05.010_bib37","doi-asserted-by":"crossref","first-page":"e0120758","DOI":"10.1371\/journal.pone.0120758","article-title":"A\u00a0multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians","volume":"10","author":"Shim","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cll.2016.05.010_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sj.tpj.6500195","article-title":"Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy","volume":"3","author":"Winkelmann","year":"2003","journal-title":"Pharmacogenomics J"},{"issue":"13","key":"10.1016\/j.cll.2016.05.010_bib39","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.cll.2016.05.010_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.cll.2016.05.010_bib42","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2016.05.010_bib43","series-title":"The biomedical engineering handbook","first-page":"1","article-title":"Physiogenomics: integrating systems engineering and nanotechnology for personalized medicine","author":"Rua\u00f1o","year":"2005"},{"key":"10.1016\/j.cll.2016.05.010_bib44","series-title":"Clinical genomics. Practical applications in adult care","first-page":"38","article-title":"Statin-induced neuromyopathy","author":"Seip","year":"2014"},{"issue":"8A","key":"10.1016\/j.cll.2016.05.010_bib45","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cll.2016.05.010_bib46","series-title":"Pharmacogenomic testing in current clinical practice: implementation in the clinical laboratory","first-page":"155","article-title":"Genotype-guided statin therapy","author":"Seip","year":"2011"},{"issue":"17","key":"10.1016\/j.cll.2016.05.010_bib47","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib48","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ahj.2013.01.025","article-title":"Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy","volume":"165","author":"Danik","year":"2013","journal-title":"Am Heart J"},{"issue":"17","key":"10.1016\/j.cll.2016.05.010_bib49","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus panel Statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cll.2016.05.010_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","author":"Needham","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib51","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy","volume":"116","author":"Rosenson","year":"2004","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.cll.2016.05.010_bib52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1875692110806030150","article-title":"The pathway less traveled: moving from candidate genes to candidate pathways in the analysis of genome-wide data from large scale pharmacogenetic association studies","volume":"6","author":"Wilke","year":"2008","journal-title":"Curr Pharmacogenomics Person Med"},{"issue":"2","key":"10.1016\/j.cll.2016.05.010_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1074248406288758","article-title":"Statin-induced myopathy: the two faces of Janus","volume":"11","author":"Arora","year":"2006","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"issue":"8A","key":"10.1016\/j.cll.2016.05.010_bib54","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.cll.2016.05.010_bib55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"issue":"9412","key":"10.1016\/j.cll.2016.05.010_bib56","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(04)15739-5","article-title":"Selenoprotein synthesis and side-effects of statins","volume":"363","author":"Moosmann","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cll.2016.05.010_bib57","first-page":"459","article-title":"Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment","volume":"143","author":"Sinzinger","year":"1999","journal-title":"Atherosclerosis"},{"issue":"5\u20136","key":"10.1016\/j.cll.2016.05.010_bib58","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/B:CARD.0000015861.26111.ab","article-title":"A\u00a0comprehensive description of muscle symptoms associated with lipid-lowering drugs","volume":"17","author":"Franc","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"10.1016\/j.cll.2016.05.010_bib59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11883-007-0050-3","article-title":"Statin myopathy: incidence, risk factors, and pathophysiology","volume":"9","author":"Sewright","year":"2007","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib60","doi-asserted-by":"crossref","first-page":"C1208","DOI":"10.1152\/ajpcell.00226.2006","article-title":"Statin-induced apoptosis and skeletal myopathy","volume":"291","author":"Dirks","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"issue":"12","key":"10.1016\/j.cll.2016.05.010_bib61","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"22","key":"10.1016\/j.cll.2016.05.010_bib62","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.cll.2016.05.010_bib63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J\u00a0Pathol"},{"issue":"23","key":"10.1016\/j.cll.2016.05.010_bib64","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cll.2016.05.010_bib65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2014.07.003","article-title":"What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?","volume":"15","author":"Santos","year":"2014","journal-title":"Atheroscler Suppl"},{"issue":"7","key":"10.1016\/j.cll.2016.05.010_bib66","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1586\/14779072.6.7.971","article-title":"Statin myopathy as a metabolic muscle disease","volume":"6","author":"Phillips","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.cll.2016.05.010_bib67","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1194\/jlr.M600301-JLR200","article-title":"Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle","volume":"48","author":"Yokoyama","year":"2007","journal-title":"J\u00a0Lipid Res"},{"issue":"1","key":"10.1016\/j.cll.2016.05.010_bib68","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.cll.2016.05.010_bib69","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.ATV.0000190608.28704.71","article-title":"Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins","volume":"25","author":"Urso","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1\u20132","key":"10.1016\/j.cll.2016.05.010_bib70","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.cll.2016.05.010_bib71","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.22100","article-title":"In\u00a0vivo and in\u00a0vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects","volume":"55","author":"Guis","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.cll.2016.05.010_bib72","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/BOR.0b013e328314b7b4","article-title":"Genetic predisposition to statin myopathy","volume":"20","author":"Vladutiu","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.cll.2016.05.010_bib73","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2011.07.007","article-title":"Mechanisms of statin-induced myalgia assessed by physiogenomic associations","volume":"218","author":"Rua\u00f1o","year":"2011","journal-title":"Atherosclerosis"},{"issue":"Pt 2","key":"10.1016\/j.cll.2016.05.010_bib74","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1042\/BJ20040261","article-title":"Isolation and functional expression of human COQ2, a gene encoding a polyprenyl transferase involved in the synthesis of CoQ","volume":"382","author":"Forsgren","year":"2004","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.cll.2016.05.010_bib75","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/ard.2007.075523","article-title":"Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study","volume":"67","author":"Sailler","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.cll.2016.05.010_bib76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cll.2016.05.010_bib77","unstructured":"Esperion Therapeutics Inc. Targeting Unmet Patient Needs: Finding new therapies for lowering LDLC for patients with hypercholesterolemia and a history of statin intolerance and for patients with residual risk. Plymouth (MI): 2013. p. 1\u20135. Available at: http:\/\/www.esperion.com\/wp-content\/uploads\/2013\/06\/Esperion-Target-Needs-Whitepaper.pdf. Accessed May 22, 2016."},{"issue":"21","key":"10.1016\/j.cll.2016.05.010_bib78","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271216300403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271216300403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T20:28:02Z","timestamp":1536611282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271216300403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0272271216300403"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2016.05.010","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2016.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}